Welcome to our dedicated page for Alexandria Real Estate Eq news (Ticker: ARE), a resource for investors and traders seeking the latest updates and insights on Alexandria Real Estate Eq stock.
Alexandria Real Estate Equities, Inc. reports news as a life science real estate investment trust that owns, operates and develops collaborative Megacampus™ ecosystems in major life science innovation clusters. Company updates commonly cover operating results, funds from operations, leasing activity, rental-rate trends and property-market demand across locations such as Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City.
Recurring announcements also include quarterly common stock dividends, balance-sheet and liquidity commentary, capital recycling activity, senior note offerings, cash tender offers for outstanding debt and corporate governance or leadership matters tied to the REIT’s public-company structure.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alexandria Real Estate Equities (NYSE: ARE) reported strong financial results for the first quarter ended March 31, 2023. Total revenues increased by 13.9% to $700.8 million from $615.1 million in Q1 2022. The company achieved a net income of $75.3 million, a significant turnaround from a loss of $151.7 million in the same period last year. Diluted earnings per share rose to $0.44 from $(0.96). Funds from operations also saw an increase, reaching $373.7 million. Alexandria's tenant collection rate remains strong at 99.9%, with 93.6% occupancy across properties. The company has maintained a flexible balance sheet with $5.3 billion in liquidity and no debt maturities until 2025. Alexandria continues to lead in the life science real estate sector, with a market capitalization of $33 billion.
Summary not available.
On April 12, 2023, Alexandria Real Estate Equities (NYSE: ARE) announced a partial interest transfer in 15 Necco Street, located in Greater Boston's Seaport Innovation District, to Mori Trust Co., Ltd. This strategic move aims to fund the construction of a 345,995 RSF Class A property, set to be completed by late 2023. The facility will host the Lilly Institute for Genetic Medicine, which focuses on advanced RNA and DNA therapies. Hunter L. Kass, the company's executive vice president, highlighted the demand for high-quality life science real estate and its long-term lease with Eli Lilly as major value drivers. The building emphasizes sustainability, targeting LEED Gold and other certifications, and aims to attract talent from Greater Boston's life science sector.
Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced a quarterly cash dividend of $1.21 per common share for Q1 2023, payable on April 14, 2023. Shareholders of record by March 31, 2023 will receive this dividend. The total annual dividend for the year ending March 31, 2023 is $4.78, reflecting a 5% increase compared to the previous year. The company projects an aggregate of $1.7 billion net cash from operations for reinvestment over the next five years while maintaining a low funds from operations (FFO) payout ratio of 58%.
Alexandria Real Estate Equities, Inc. (NYSE: ARE) announced a conference call and audio webcast on April 25, 2023, at 3:00 p.m. ET, to discuss its first quarter 2023 operating and financial results. The financial results will be released post-market on April 24, 2023. Investors can join the call by dialing (833) 366-1125 for the U.S. or (412) 902-6738. A live audio webcast will be available on the company's website, with a replay accessible from 5:00 p.m. ET on April 25, 2023 to 5:00 p.m. ET on May 2, 2023. Alexandria Real Estate Equities is a leading life science REIT, specializing in properties in key innovation clusters.